We address public health needs by developing a self-amplifying RNA-based platform for rapid and scalable manufacturing of innovative medical tools.

Our Technology

Lipid nanoparticle

The in-house developed LNP library at Ziphius is specifically designed for saRNA delivery and ensures proper encapsulation, stability, and biodegradability of the LNP-saRNA complex. Furthermore, Ziphius is also focused on making LNPs for various administration routes for vaccination and supplementation therapies. The platform is being optimized to target specific organs and tissues, to minimize acute and chronic toxicity, and to acquire the most optimal prophylactic vaccination or gene supplementation effect.


Lottie file

Self-amplifying RNA

Over conventional mRNA, saRNA contains the replicating capability to amplify the copy number of coding sequences from a single transcript. saRNAs are able to carry larger sequences while generating more RNA. saRNAs are then expected to induce equal or higher required ‘product’ at a much lower dosage.

Lottie file


Ziphius aims to leverage the use of its self-amplifying RNA platform to create vaccines for the prevention of infectious diseases and gene supplementation therapies for rare genetic disorders.


Join our team

Ziphius Vaccines’ team consists of a well-balanced group of people with complementary skills and a background ranging from biology, virology, chemistry till pharmaceutical sciences. The team members are united by their common passion for science, health care, innovation and entrepreneurship.

Latest news


There are no upcoming events at this time.